Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

24.86 +0.06 (+0.24%)
Official Closing Price Updated: 7:00 PM EST, Nov 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
Stocks Surge On Healthy Earnings Season, Rising Jobless Claims: This Week In The Markets
Week in markets: quiet week, Q1 earnings positive, S&P 500 and Dow Jones up, utilities sector stands out, job market and inflation concerns, interest rate cuts expected. Buffett reduces Apple stake,... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
2 Beaten-Down Stocks to Buy and Hold for 10 Years
They offer plenty of upside and solid dividend growth. 
Via The Motley Fool
FDA Delays 'Important' Moderna Vaccine Review: William Blair Says 2025 Growth, '2026 Breakeven Story' Depends On It
FDA update: Moderna's BLA for mRNA-1345, RSV vaccine, may face delay past May 12 deadline. But no safety concerns reported. 
Via Benzinga
Exposures Product Safety
Moderna Dives Back Into Buy Zone After FDA Delays Its RSV Vaccine
The FDA hasn't said there are any vaccine effectiveness, safety or quality issues that would prevent approval, Moderna says. 
Via Investor's Business Daily
Exposures Product Safety
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields
Via Benzinga
Spotlight on Pfizer: Analyzing the Surge in Options Activity
Via Benzinga
Pfizer's Options Frenzy: What You Need to Know
Via Benzinga
7 F-Rated Stock Picks to Avoid Like the Plague in May
Consumer stocks, electric vehicle companies and meme stocks top the list of F-rated stock picks to avoid this month. 
Via InvestorPlace
Topics Electric Vehicles
Exposures Electric Vehicles
3 Biotech Stocks to Sell in May Before They Crash & Burn
Discover essential insights on biotech stocks to sell in May to navigate market volatility and safeguard your investment portfolio. 
Via InvestorPlace
The 3 Most Undervalued Healthcare Stocks to Buy in May 2024
These are the undervalued healthcare stocks to buy as they represent companies with steady growth visibility. 
Via InvestorPlace
Safeguard Your Future: Top 3 Stocks to Weather Any Market Downturn
Explore three stocks that will resist a market downturn that offer both stability and potential growth during economic fluctuations. 
Via InvestorPlace
3 Profitable Dividend Stocks to Buy at Near-Lows
With high yields above 3% and dirt-cheap valuations, these undervalued dividend stocks present a significant margin of safety. 
Via InvestorPlace
7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025
The second wave of the weight loss drug stock boom is underway and investors should heed the signs the market is serving. 
Via InvestorPlace
2 No-Brainer Dividend Stocks to Buy in May
These two blue chip dividend stocks are top buys right now. 
Via The Motley Fool
Elon Musk Breaks Ranks With GOP By Praising Genetic Engineering Tech That Helped Fight COVID-19: 'Digital Medicine With Incredible Potential'
Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists. 
Via Benzinga
This 6% Yielding Dividend Stock Could Pump Up Your Passive-Income Stream
Pfizer's new product lineup could allow the pharmaceutical giant to push its dividend steadily higher for another 15 years. 
Via The Motley Fool
Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac
Pfizer settles 10,000 Zantac lawsuits over cancer risks, but challenges remain. Details undisclosed. Sanofi's $100 million+ agreement also noted. Legal battles ongoing. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Second Death - Pfizer Reports Young Boy's Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder Trial
A young patient passed away from cardiac arrest after receiving Pfizer's experimental gene therapy for Duchenne muscular dystrophy. Pfizer investigates while trials continue, including Phase 3 study.... 
Via Benzinga
Just Say No to Drugs: 3 Pharma Stocks to Avoid
Discover which pharma stocks to avoid in 2023 as we delve into market trends, financial struggles, and the impact on investor portfolios. 
Via InvestorPlace
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
EQNX::TICKER_START (OTCPK:MUSLF),(CSE:MUSL),(NYSE:MRK),(NYSE:PFE),(NASDAQ:MRNA),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024
From FN Media Group LLC
Via GlobeNewswire
Got $1,000? 3 Dividend Stocks to Buy and Hold Forever
Check out these healthcare stocks for some healthy payouts. 
Via The Motley Fool
Jim Cramer Advises Investors To Brace For Economic Slowdown, Shares Tips To Maintain Balanced Portfolio: 'I'm Not Telling You To Relax'
Jim Cramer, the host of CNBC's "Mad Money," has warned investors about the current state of the economy and suggested strategies to navigate the challenging period. 
Via Benzinga
Topics Economy
Exposures Economy
A Look At Pharma ETFs Post Q1 Earnings
Pharma ETFs have delivered mixed performances over the past month. 
Via Talk Markets
Topics ETFs
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy. 
Via InvestorPlace
Tuesday Talk: Still Flying
The stock market is still on the upswing. For all the anti-Fed pundits, the market seems to be going with Chairman Powell for now. 
Via Talk Markets
Maximize Your Dividends: 7 Stocks Trading Under $50 with 5%+ Yields
Investing in high-yield dividend stocks under $50 is a low-risk strategy that can result in massive returns in time. 
Via InvestorPlace
What's Going With BioNTech Stock On Monday?
BioNTech reports Q1 loss, missing revenue expectations. Despite challenges, BioNTech aims for significant growth, fueled by innovative R&D and strong cash reserves. 
Via Benzinga
Pfizer Announces New Chief Strategy and Innovation Officer
From Pfizer Inc.
Via Business Wire
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
After a painful two-year selloff, Pfizer shareholders may have finally gained a foothold after the company delivered a solid Q1 2024 earnings report 
Via MarketBeat
Exposures COVID-19
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS